Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Overdose Harm Reduction topic
No spam. Unsubscribe anytime.
Georgia Senate committee approves bill to broaden drug-checking tools to detect xylazine and other adulterants
Summary
The Senate committee approved Senate Bill 6 to expand legal use of drug-checking tools beyond fentanyl test strips to include xylazine and other adulterants; proponents said the measure is intended to save lives amid a rise in xylazine-involved overdose deaths.
Senator Kay Kirkpatrick introduced Senate Bill 6 to the Georgia Senate Health Committee, saying the measure would expand the state's existing authorization for fentanyl test strips to cover xylazine and other emerging drug adulterants.
"This bill simply broadens the bill that we passed previously to include tools like xylazine test strips, which now do exist, and tests for other adulterants," Senator Kay Kirkpatrick told the committee, describing the measure as a short, narrowly focused change. She said the number of overdose deaths involving xylazine has risen and that xylazine is not reversed by naloxone because it is not an opioid.
The nut graf: Sponsors and harm-reduction advocates said the bill responds to a shifting drug supply that now includes non-opioid adulterants such as xylazine, which they say has increased in involvement with Georgia overdose deaths since 2022. The committee approved the bill by voice vote.
Supporters told the committee they believe broader access to drug-checking tools will reduce fatalities. Jeff Breedlove, speaking for the Georgia Council for Recovery, said, "This bill will save lives," and described witnessing xylazine overdoses during recent visits to Philadelphia's Kensington neighborhood. Mark Bridal, director of state government affairs at the R Street Institute, framed the measure as harm reduction that complements prevention and treatment: "Even with the best prevention and treatment tools in place, some people will continue to take illicit substances. So we try to reduce harm where it can't be eliminated."
Senator Kirkpatrick and witnesses cited national reporting and Drug Enforcement Administration attention to xylazine and other adulterants. The sponsor told the committee the bill does not list specific substances but is written to accommodate future, unforeseeable adulterants by broadening the existing statutory language that authorized synthetic-opioid test strips.
The committee recorded a motion, a second and a voice vote; no roll-call tally was provided in the transcript. A committee member noted the bill's house sponsor and an internal legislative identifier were on the record as LC520718SSCS.
Ending: The committee chair declared the bill passed by voice vote. Proponents framed the measure as an incremental harm-reduction step while longer-term prevention and treatment strategies continue.
